Clinical Trial

The Natural History of Mitochondrial Diseases

Recruiting
View on ClinicalTrials.gov →
Summary
The Natural History of Mitochondrial (MITO) Diseases (a longitudinal study observing the natural history of mitochondrial diseases) The goal of this observational study (non-randomised retrospective and prospective) is to fully characterise primary MITO disease; that includes both sexes/genders, over 18 years of age and healthy volunteers\]. The main question\[s\] it aims to answer is to: • better characterise MITO phenotypes (organ involvement, severity, progression) and collect biospecimens to create a biobank that can be used for future biomarker discovery to improve early diagnosis, prognostication and management of mitochondrial disease. The study will be a longitudinal, retrospective, prospective, observational study of participants (400) with confirmed MITO and relevant controls followed for up to 10 years. Data will be collected at regularly scheduled standard-of-care (SOC), 6 to 12 monthly appointments. The 100 control participants will therefore be comprised of (i) unaffected asymptomatic family members of MITO participants with no genetic risk; (ii) participants with non-MITO movement disorders that are not classified as MITO by their clinical presentation and genetic tests (for example Parkinson's disease) and/or (iii) age-matched healthy controls recruited from the NeuRA database of volunteers. Demographic data, medical history, biochemical, histological, genetic, social and other clinical SOC data will be collected. Additionally, seizure and migraine frequency in participants who experience these, will be collected and a quality-of-life questionnaire (SF-12v2), as part of the validated neurological assessment using the Newcastle Mitochondrial Disease Adult Scale (NMDAS).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-11.
Trial Details
NCT Number NCT06504433
Lead Sponsor Neuroscience Research Australia
Conditions Mitochondrial Diseases, Neurological Diseases or Conditions, Genetic Disease
Enrollment 500 participants
Start Date 2024-05-07
Primary Completion 2029-05-07 (estimated)
Study Completion 2034-05-07 (estimated)
Updated on ClinicalTrials.gov 2026-04-20